BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

414 related articles for article (PubMed ID: 25829425)

  • 1. MYC Drives Pten/Trp53-Deficient Proliferation and Metastasis due to IL6 Secretion and AKT Suppression via PHLPP2.
    Nowak DG; Cho H; Herzka T; Watrud K; DeMarco DV; Wang VM; Senturk S; Fellmann C; Ding D; Beinortas T; Kleinman D; Chen M; Sordella R; Wilkinson JE; Castillo-Martin M; Cordon-Cardo C; Robinson BD; Trotman LC
    Cancer Discov; 2015 Jun; 5(6):636-51. PubMed ID: 25829425
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The PHLPP2 phosphatase is a druggable driver of prostate cancer progression.
    Nowak DG; Katsenelson KC; Watrud KE; Chen M; Mathew G; D'Andrea VD; Lee MF; Swamynathan MM; Casanova-Salas I; Jibilian MC; Buckholtz CL; Ambrico AJ; Pan CH; Wilkinson JE; Newton AC; Trotman LC
    J Cell Biol; 2019 Jun; 218(6):1943-1957. PubMed ID: 31092557
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A balancing act: PHLPP2 fine tunes AKT activity and MYC stability in prostate cancer.
    Toivanen R; Furic L
    J Cell Biol; 2019 Jun; 218(6):1771-1772. PubMed ID: 31145683
    [TBL] [Abstract][Full Text] [Related]  

  • 4. RapidCaP, a novel GEM model for metastatic prostate cancer analysis and therapy, reveals myc as a driver of Pten-mutant metastasis.
    Cho H; Herzka T; Zheng W; Qi J; Wilkinson JE; Bradner JE; Robinson BD; Castillo-Martin M; Cordon-Cardo C; Trotman LC
    Cancer Discov; 2014 Mar; 4(3):318-33. PubMed ID: 24444712
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PTEN, more than the AKT pathway.
    Blanco-Aparicio C; Renner O; Leal JF; Carnero A
    Carcinogenesis; 2007 Jul; 28(7):1379-86. PubMed ID: 17341655
    [TBL] [Abstract][Full Text] [Related]  

  • 6. NKX3.1 stabilizes p53, inhibits AKT activation, and blocks prostate cancer initiation caused by PTEN loss.
    Lei Q; Jiao J; Xin L; Chang CJ; Wang S; Gao J; Gleave ME; Witte ON; Liu X; Wu H
    Cancer Cell; 2006 May; 9(5):367-78. PubMed ID: 16697957
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Loss of Nkx3.1 leads to the activation of discrete downstream target genes during prostate tumorigenesis.
    Song H; Zhang B; Watson MA; Humphrey PA; Lim H; Milbrandt J
    Oncogene; 2009 Sep; 28(37):3307-19. PubMed ID: 19597465
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combined MYC Activation and Pten Loss Are Sufficient to Create Genomic Instability and Lethal Metastatic Prostate Cancer.
    Hubbard GK; Mutton LN; Khalili M; McMullin RP; Hicks JL; Bianchi-Frias D; Horn LA; Kulac I; Moubarek MS; Nelson PS; Yegnasubramanian S; De Marzo AM; Bieberich CJ
    Cancer Res; 2016 Jan; 76(2):283-92. PubMed ID: 26554830
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of targeted AKT inhibition in genetically engineered mouse models of PTEN-deficient prostate cancer.
    De Velasco MA; Kura Y; Yoshikawa K; Nishio K; Davies BR; Uemura H
    Oncotarget; 2016 Mar; 7(13):15959-76. PubMed ID: 26910118
    [TBL] [Abstract][Full Text] [Related]  

  • 10. AKT-mediated stabilization of histone methyltransferase WHSC1 promotes prostate cancer metastasis.
    Li N; Xue W; Yuan H; Dong B; Ding Y; Liu Y; Jiang M; Kan S; Sun T; Ren J; Pan Q; Li X; Zhang P; Hu G; Wang Y; Wang X; Li Q; Qin J
    J Clin Invest; 2017 Apr; 127(4):1284-1302. PubMed ID: 28319045
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Estrogen receptor alpha drives proliferation in PTEN-deficient prostate carcinoma by stimulating survival signaling, MYC expression and altering glucose sensitivity.
    Takizawa I; Lawrence MG; Balanathan P; Rebello R; Pearson HB; Garg E; Pedersen J; Pouliot N; Nadon R; Watt MJ; Taylor RA; Humbert P; Topisirovic I; Larsson O; Risbridger GP; Furic L
    Oncotarget; 2015 Jan; 6(2):604-16. PubMed ID: 25436982
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of PHLPP1 as a tumor suppressor reveals the role of feedback activation in PTEN-mutant prostate cancer progression.
    Chen M; Pratt CP; Zeeman ME; Schultz N; Taylor BS; O'Neill A; Castillo-Martin M; Nowak DG; Naguib A; Grace DM; Murn J; Navin N; Atwal GS; Sander C; Gerald WL; Cordon-Cardo C; Newton AC; Carver BS; Trotman LC
    Cancer Cell; 2011 Aug; 20(2):173-86. PubMed ID: 21840483
    [TBL] [Abstract][Full Text] [Related]  

  • 13. c-Jun NH(2)-terminal kinase mediates leptin-stimulated androgen-independent prostate cancer cell proliferation via signal transducer and activator of transcription 3 and Akt.
    Miyazaki T; Bub JD; Iwamoto Y
    Biochim Biophys Acta; 2008 Oct; 1782(10):593-604. PubMed ID: 18718531
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer.
    Carver BS; Chapinski C; Wongvipat J; Hieronymus H; Chen Y; Chandarlapaty S; Arora VK; Le C; Koutcher J; Scher H; Scardino PT; Rosen N; Sawyers CL
    Cancer Cell; 2011 May; 19(5):575-86. PubMed ID: 21575859
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Activation of Akt signaling in prostate induces a TGFβ-mediated restraint on cancer progression and metastasis.
    Bjerke GA; Yang CS; Frierson HF; Paschal BM; Wotton D
    Oncogene; 2014 Jul; 33(28):3660-7. PubMed ID: 23995785
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relationship between polycomb-group protein BMI-1 and phosphatases regulating AKT phosphorylation level in endometrial cancer.
    Zaczek A; Jóźwiak P; Ciesielski P; Forma E; Wójcik-Krowiranda K; Cwonda Ł; Bieńkiewicz A; Bryś M; Krześlak A
    J Cell Mol Med; 2020 Jan; 24(2):1300-1310. PubMed ID: 31863623
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gata3 antagonizes cancer progression in Pten-deficient prostates.
    Nguyen AH; Tremblay M; Haigh K; Koumakpayi IH; Paquet M; Pandolfi PP; Mes-Masson AM; Saad F; Haigh JJ; Bouchard M
    Hum Mol Genet; 2013 Jun; 22(12):2400-10. PubMed ID: 23428429
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In Vivo Role of INPP4B in Tumor and Metastasis Suppression through Regulation of PI3K-AKT Signaling at Endosomes.
    Li Chew C; Lunardi A; Gulluni F; Ruan DT; Chen M; Salmena L; Nishino M; Papa A; Ng C; Fung J; Clohessy JG; Sasaki J; Sasaki T; Bronson RT; Hirsch E; Pandolfi PP
    Cancer Discov; 2015 Jul; 5(7):740-51. PubMed ID: 25883022
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cooperation between FGF8b overexpression and PTEN deficiency in prostate tumorigenesis.
    Zhong C; Saribekyan G; Liao CP; Cohen MB; Roy-Burman P
    Cancer Res; 2006 Feb; 66(4):2188-94. PubMed ID: 16489020
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PTEN loss mediated Akt activation promotes prostate tumor growth and metastasis via CXCL12/CXCR4 signaling.
    Conley-LaComb MK; Saliganan A; Kandagatla P; Chen YQ; Cher ML; Chinni SR
    Mol Cancer; 2013 Jul; 12(1):85. PubMed ID: 23902739
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.